Search results for "Adverse effect"

showing 10 items of 1065 documents

Effects of Rapid Weight Loss on Kidney Function in Combat Sport Athletes

2021

Even though scientific literature shows numerous heath complications and performance decrements associated with rapid weight loss (RWL), its prevalence remains exceedingly high across various combat sports. The aim of this study was to thoroughly search the existing literature to explore the influence of RWL on kidney function in Olympic and non-Olympic combat sport athletes. PubMed and Web of Science were searched for the relevant studies. Only original articles published from 2005 onwards, written in English, that included healthy males and females who prompted ~5% weight loss within a week or less, were included in the study. Retrieved studies showed that creatinine, blood urea nitrogen …

MaleMedicine (General)medicine.medical_specialtymaking weightRenal function030209 endocrinology & metabolismReviewKidneyBlood urea nitrogen; Creatinine; Health; Making weight; Performance; Renal system; Urine specific gravity; Weight cutting; Athletes; Body Weight; Female; Humans; Kidney; Male; Martial Arts; Weight Loss03 medical and health scienceschemistry.chemical_compoundR5-9200302 clinical medicineweight cuttingurine specific gravityWeight lossSettore BIO/10 - BiochimicaWeight LossmedicineHumansrenal systemAdverse effectBlood urea nitrogenblood urea nitrogenCreatininebiologyAthletesUrine specific gravityRapid weight lossbusiness.industryBody Weightcreatininehealth030229 sport sciencesGeneral Medicinebiology.organism_classificationchemistryAthletesPhysical therapyFemalemedicine.symptombusinessperformanceMartial ArtsMedicina
researchProduct

A 6 day course of liposomal amphotericin B in the treatment of infantile visceral leishmaniasis: the Italian experience

2004

Objectives To evaluate in a retrospective analysis the efficacy and safety of a 6 day course of liposomal amphotericin B (L-AmB) in infantile cases of Mediterranean visceral leishmaniasis (VL) diagnosed over a 10 year period in Italy. Patients and methods Patients included were diagnosed as having VL consecutively admitted from December 1992 to December 2001 at four main referral children's hospitals in Italy and treated with six intravenous doses of 3 mg/kg L-AmB given on days 1-5 and 10 (a total dose of 18 mg/kg). Demographic data, nutritional status, underlying diseases, clinical and laboratory findings, and therapy outcome were considered. Results A total of 164 HIV-negative children (m…

MaleMicrobiology (medical)medicine.medical_specialtyAdolescentFeverAntiprotozoal AgentsFluorescent Antibody TechniqueNutritional Statusitaly; leishmania infantum; therapyBone MarrowRecurrenceAmphotericin BInternal medicineAmphotericin BmedicineHumansPharmacology (medical)ChildAdverse effectleishmaniasisRetrospective StudiesPharmacologyDrug Carriersbiologybusiness.industryInfantRetrospective cohort studyLeishmaniasismedicine.diseasebiology.organism_classificationSurgeryRegimenTreatment OutcomeInfectious DiseasesVisceral leishmaniasisItalyEl NiñoChild PreschoolLiposomesLeishmaniasis VisceralFemaleLeishmania infantumbusinessmedicine.drug
researchProduct

Trichobiolight: A new, effective protocol in the treatment of androgenetic alopecia and telogen effluvium

2021

Androgenetic alopecia (AGA) with its precursor miniaturization of anagen phase (MA) and telogen effluvium (TE) represent nonscarring hair loss diseases which causes moderate to severe aesthetic and psychologic discomfort in affected people. Several therapeutic approaches have been tested through the latest decades, with different degree of success. In this study we aim to analyze the efficacy and outcome of an innovative therapeutic protocol, named TRICHOBIOLIGHT, a combination of active principles conveyed by mesotherapy directly on the scalp with a subsequent photobiostimulation session with LED light (630 nm). About 107 patients (49 women, 58 men, mean age 45-year-old) with clinical and …

MaleModerate to severemedicine.medical_specialtyAlopecia AreataDermatologyScarring alopeciaTelogen effluvium030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinemedicineHumansAdverse effectScalpintegumentary systembusiness.industryAlopeciaGeneral MedicineMiddle Agedmedicine.diseaseDermatologyMesotherapyHair lossmedicine.anatomical_structureItaly030220 oncology & carcinogenesisScalpFemaleThickeningbusinessHairDermatologic Therapy
researchProduct

The use of pilocarpine in opioid-induced xerostomia

2001

Oral dryness can be a symptom of asystemic disease, an adverse effect of anticholin-ergic, antiadrenergic or cytotoxic drug treatment, orit can be due to local radiotherapy. Opioid use isstrongly associated with xerostomia, although themechanism for this remains unclear; in one studypatients receiving morphine were four times morelikely to have a dry mouth than patients taking otherdrugs known to cause xerostomia.

MaleNarcoticsmedicine.medical_specialtyPalliative caremedicine.medical_treatmentAdministration OralPainMuscarinic AgonistsXerostomiaGastroenterologyMuscarinic Agonist03 medical and health sciences0302 clinical medicinestomatognathic system030502 gerontologyNeoplasmsInternal medicinemedicineHumansAdverse effectAgedChemotherapybusiness.industryPilocarpinefood and beveragesGeneral MedicineMiddle AgedDry mouthstomatognathic diseasesTreatment OutcomeAnesthesiology and Pain MedicineOpioidPilocarpineNarcotic030220 oncology & carcinogenesisAnesthesiaToxicityMorphineNeoplasmFemalemedicine.symptom0305 other medical sciencebusinessHumanmedicine.drugPalliative Medicine
researchProduct

Inorganic arsenic exposure and neuropsychological development of children of 4-5 years of age living in Spain

2019

This study was funded by grants from Spanish Institute of Health Carlos III-Ministry of Economy and Competitiveness (INMA Network G03/176, CB06/02/0041, and FIS-FEDER: PI03/1615, PI04/1436, PI08/1151, PI04/2018, PI04/1509, PI04/1112, PI04/1931, PI05/1079, PI05/1052, PI06/1213, PI06/0867, PI07/0314, PI09/02647, PS09/00090, PI09/02311, MS11/0178, PI13/1944, PI13/2032, PI14/00891, PI16/1288, and PI17/00663). Miguel Servet-FEDER: MSII16/ 00051, CP14/00108 & PI16/00261 (Co-funded by European Regional Development Fund “A way to make Europe”), FEDER funds, MS13/00054. Generalitat de Catalunya-CIRIT 1999SGR 00241, JCI2011–09771–MICINN, Generalitat Valenciana (Conselleria de Sanitat048/2010 and 060/…

MaleNeurodevelopmentMcCarthy scales of Children's abilitiesDevelopmental toxicologyUrine010501 environmental sciencesNeuropsychological developmentEnvironment01 natural sciencesBiochemistryArsenicalsArticleArsenic03 medical and health scienceschemistry.chemical_compound0302 clinical medicineChild DevelopmentInterquartile rangeCacodylic acidMedicineCacodylic AcidHumans030212 general & internal medicineChildren Developmental toxicology Dietary arsenic Environment Inorganic arsenic McCarthy scales of Children's abilities Neurodevelopment Neuropsychological development Urinary arsenic speciesAdverse effectChildChildren0105 earth and related environmental sciencesGeneral Environmental ScienceUrinary arsenic speciesbusiness.industryDietary ArsenicConfoundingInorganic arsenicEnvironmental ExposureMcCarthy Scales of Children's AbilitiesConfidence intervalDietCross-Sectional StudieschemistryDietary arsenicSpainChild PreschoolFemalebusinessDemographyEnvironmental Research
researchProduct

Peptide Receptor Radionuclide Therapy Combined With Chemotherapy in Patients With Neuroendocrine Tumors

2019

Combinations of therapies may enhance therapeutic effects without significantly increasing the incidence of adverse events. However, there are few data regarding survival after concomitant chemotherapy and peptide receptor radionuclide therapy (PRRT) with [Lu]Lu-octreotate in patients with neuroendocrine tumors (NETs). Thus, we explored the outcome of this combination of therapies.Fifteen patients with somatostatin receptor-positive, rapidly progressive G2/G3 NETs during chemotherapy or PRRT alone from 2 German cancer centers were included in the retrospective analysis. The patients received a combination of PRRT and chemotherapy with temozolomide (n = 3) or temozolomide plus capecitabine (…

MaleOncologyAntimetabolites Antineoplasticmedicine.medical_specialtyPeptide receptormedicine.medical_treatmentNeuroendocrine tumorsOctreotide030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePositron Emission Tomography Computed TomographyInternal medicineOrganometallic CompoundsTemozolomidemedicineHumansRadiology Nuclear Medicine and imagingAdverse effectCapecitabineAgedChemotherapybusiness.industryIncidence (epidemiology)Therapeutic effectChemoradiotherapyGeneral MedicineMiddle Agedmedicine.diseaseNeuroendocrine Tumors030220 oncology & carcinogenesisConcomitantRadionuclide therapyFemaleRadiopharmaceuticalsbusinessClinical Nuclear Medicine
researchProduct

Phase ia/ii, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematolo…

2013

Panobinostat is a potent oral pandeacetylase inhibitor that leads to acetylation of intracellular proteins, inhibits cellular proliferation and induces apoptosis in leukemic cell lines. A phase Ia/II study was designed to determine the maximum-tolerated dose (MTD) of daily panobinostat, administered on two schedules: three times a week every week or every other week on a 28-day treatment cycle in patients with advanced hematologic malignancies. The criteria for hematologic dose-limiting toxicities differed between patients with indications associated with severe cytopenias at baseline (leukemia and myeloid disorders) and those less commonly associated with baseline cytopenias (lymphoma and …

MaleOncologyCancer ResearchIndolesMyeloidhodgkin lymphomahydroxamic acidAdministration Oralresponse criteriaPharmacologyHydroxamic Acidst-cell lymphomaHistoneschemistry.chemical_compoundhemic and lymphatic diseasesAged 80 and overHematologyMiddle AgedLeukemiaTreatment Outcomemedicine.anatomical_structuremyelomaOncologyvorinostatHematologic NeoplasmsFemaleAdultmedicine.medical_specialtypanobinostatrefractory multiple-myelomaMaximum Tolerated DoseAntineoplastic AgentsmyelofibrosisNeutropeniahistone deacetylase inhibitorsmyelodysplastic disordersDrug Administration ScheduleYoung AdultInternal medicinePanobinostatmedicineHumansIn patientAdverse effectMyelofibrosisAgedNeoplasm Staginginternational-working-groupacetylationbusiness.industrymedicine.diseaseLymphomachemistryhistone deacetylasehypoxia-inducible factor-1-alphalbh589business
researchProduct

Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients.

2013

Bevacizumab is a humanized anti-VeGF monoclonal antibody able to produce clinical beneit in advanced non-squamous non-small cell lung cancer (nsCLC) patients when combined to chemotherapy. At present, while there is a rising attention to bevacizumab-related adverse events and costs, no clinical or biological markers have been identiied and validated for baseline patient selection. preclinical indings suggest an important role for myeloid-derived inlammatory cells, such as neutrophils and monocytes, in the development of VeGF-independent angiogenesis. We conducted a retrospective analysis to investigate the role of peripheral blood cells count and of an inlammatory index, the neutrophil-toly…

MaleOncologyCancer ResearchLung NeoplasmsNeutrophilsmedicine.medical_treatmentPlatinum CompoundsMonocyteCarcinoma Non-Small-Cell LungAntineoplastic Combined Chemotherapy ProtocolsNeutrophil-to-lymphocyte ratioUnivariate analysisadvanced non-small cell lung cancerMiddle AgedBevacizumabAngiogenesiTreatment OutcomeOncologyMolecular MedicineFemalemedicine.symptomLung cancermedicine.drugmedicine.medical_specialtyBevacizumabInflammationAntibodies Monoclonal HumanizedDisease-Free SurvivalInternal medicinemedicineHumansLymphocyte CountNeutrophil to lymphocyte ratioLung cancerAdverse effectAgedNeoplasm StagingRetrospective StudiesPharmacologyInflammationChemotherapyBedside to Bench ReportPlatelet Countbusiness.industryRetrospective cohort studymedicine.diseaseMultivariate AnalysisImmunologybusinessSystemic inflammatory status
researchProduct

Methadone response in advanced cancer patients with pain followed at home

1999

Concerns about the safety of therapy with methadone, which may arise because of its pharmacokinetic characteristics and inappropriate dosing, may deter clinicians from using this drug, especially in elderly patients. Experience is accumulating that the drug may be used safely and successfully if low doses are given initially and care is taken in the titration of the dose against the pain. A prospective study was carried out in a consecutive sample of 45 advanced cancer patients followed at home, who had never received other strong opioids for their pain. Patients were treated with an oral liquid preparation of methadone, which was administered 2-3 times daily, according to need. Doses were …

MaleOpioidAdverse effectSex FactorsNeoplasmsHumansMedicineProspective StudiesDosingCancer painAdverse effectProspective cohort studyGeneral NursingNursing (all)2901 Nursing (miscellaneous)Pain Measurementbusiness.industryMiddle AgedHome Care ServicesMiddle agePain IntractableAnalgesics OpioidAnesthesiology and Pain MedicineAnesthesiaNeuropathic painAmbulatoryFemaleNeurology (clinical)businessCancer painMethadoneMethadonemedicine.drug
researchProduct

Low-level laser therapy and anesthetic infiltration for orofacial pain in patients with fibromyalgia : a randomized clinical trial

2018

Background To compare the analgesic effect of anesthetic infiltration of lidocaine 2% and low-level laser therapy (LLLT) by GaAlAs into tender points of patients with orofacial pain and fibromyalgia (FM). Material and Methods A randomized clinical trial was performed with adults (N=66) that were allocated into two groups (1:1): Group A received LLLT irradiation by Diode Laser GaAlAs (780nm) with expositions twice a week during six weeks and Group B was treated with anesthetic infiltration of lidocaine 2% without vasoconstrictor once a week for four weeks. The pain assessment included the Visual Analogic Scale (VAS) and tenderness to palpation. Results No dropout and adverse effect was obser…

MaleOrofacial painFibromyalgiaLidocainemedicine.medical_treatmentlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialFacial PainlawPain assessmentFibromyalgiaHumansPain ManagementMedicineAnesthetics LocalLow-Level Light TherapyAdverse effectGeneral DentistryLow level laser therapybusiness.industryResearchLidocaine030206 dentistryMiddle AgedMedically compromised patients in Dentistrymedicine.disease:CIENCIAS MÉDICAS [UNESCO]OtorhinolaryngologyAnesthesiaUNESCO::CIENCIAS MÉDICASAnestheticFemaleSurgeryLasers Semiconductormedicine.symptombusiness030217 neurology & neurosurgeryAnesthesia Localmedicine.drug
researchProduct